TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02562053
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
Study: NCT02562053
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive a daily oral placebo similar to fluoxetine
Study: NCT00122668
Drug: non-nucleoside reverse transcriptase inhibitors
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122668
Drug: nucleoside reverse transcriptase inhibitors
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122668
Drug: protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02407821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
Study: NCT00352560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 30 days.
Study: NCT02324569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT00479609
Drug: Transdermal testosterone therapy
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone 1% hydroalcohol gel
Study: NCT00479609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: NCT03684395
Drug: Standard of care (Warfarin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Study: NCT01092455
Drug: Heparin N reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
Study: NCT04254471
Drug: AL3810
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mgQD, 7.5mgQD, 10mgQD
Study: NCT06416241
Drug: EYLEA 2 MG in 0.05 ML Injection
Normalized name: EYLEA 2 MG in 0.05 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT04254471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00889486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03375957
Drug: ATx201
Approvals — FDA: no, EMA: no, PMDA: no
Description: two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
Study: NCT03751488
Drug: LY03010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of LY03010 at 351 mg or 156 mg or 117mg
Study: NCT03751488
Drug: Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Normalized name: Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose at 156mg
Study: NCT03375957
Drug: ATx201 Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
Study: NCT00719134
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT00719134
Drug: placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT00003454
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01592981
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.
Study: NCT02073773
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.
Study: NCT01264497
Drug: TH9507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 and 2 mg, sc daily for 12 weeks
Study: NCT03126760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for subcutaneous injection
Study: NCT00592384
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
Study: NCT02433483
Drug: Intrathecal Triples
Approvals — FDA: no, EMA: no, PMDA: no
Description: given IT.
Study: NCT03780907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
Study: NCT01250405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
Study: NCT02352402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02648776
Drug: Exposure to sedative-hypnotic drugs
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
Study: NCT03733002
Drug: AngongNiuhuang pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
Study: NCT03733002
Drug: Placebo of AngongNiuhuang pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
Study: NCT00048555
Drug: IDEC-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
Study: NCT02153099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-058 (ENV8058) placebo-matching oral solution
Study: NCT00828321
Drug: Altace® 10 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT03007524
Drug: High dose Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/d qN, at least 6 months
Study: NCT03007524
Drug: Low dose Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/d qN, at least 6 months
Study: NCT02878018
Drug: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
Study: NCT04005222
Drug: MELATONIN
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
Study: NCT01354886
Drug: FSH-GEX™
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01193868
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01102504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00673465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
Study: NCT03879564
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
Study: NCT00808977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching active and experimental treatments
Study: NCT03018704
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive medication. the doses of placebo were titrated the same as the active intervention.
Study: NCT04383795
Drug: Antithyroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antithyroid Drug for 6 months
Study: NCT01110434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily)
Study: NCT00495183
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
Study: NCT00495183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04135898
Drug: SIBP-04
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg, infusion in 90 minutes
Study: NCT01092104
Drug: TBR-652
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 25 mg
Study: NCT01092104
Drug: TBR-652 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01092104
Drug: TBR-652 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 50 mg QD for 10 days
Study: NCT03569995
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory
Study: NCT01092104
Drug: TBR-652 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 75 mg QD for 10 days
Study: NCT01092104
Drug: TBR-652 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 100 mg QD for 10 days
Study: NCT01092104
Drug: TBR-652 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 150 mg QD for 10 days
Study: NCT01709162
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492037
Drug: YM087 oral
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02601378
Drug: LXS196
Approvals — FDA: no, EMA: no, PMDA: no
Description: LXS196 as a single agent
Study: NCT02102815
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS 50 mL IV slowly push over 5 minutes
Study: NCT02183311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00918645
Drug: 41 Ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
Study: NCT00865384
Drug: REMERON® 15 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
Study: NCT04415073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00697671
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study: NCT01275209
Drug: HCD122
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02496611
Drug: Weight loss with pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the drug intervention group will receive Exenatide extended-release.
Study: NCT02496611
Drug: Weight loss without pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo group will receive a placebo.
Study: NCT01903837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken once daily
Study: NCT01804465
Drug: SipT Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion.
Study: NCT02393144
Drug: Cervical ripening, labor induction, Dinoprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of dinoprostone pessary for cervical ripening and labor induction.
Study: NCT00620867
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg oral tablet three time daily with meals for 6 weeks
Study: NCT00620867
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study: NCT00540423
Drug: SB-497115-GR 12.5mg matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
Study: NCT06626607
Drug: CCB use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antihypertensive medication includes CCB
Study: NCT06626607
Drug: non-CCB use
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antihypertensive medication does not include CCB
Study: NCT03431961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 14 days
Study: NCT01748773
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
Study: NCT00276744
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study: NCT02742480
Drug: Acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02771912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative composition of Propofol lipuro 2% excipients
Study: NCT02725710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
Study: NCT01406080
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
Study: NCT02448160
Drug: salt-poor Human Albumin solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
Study: NCT00719420
Drug: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
Study: NCT00719420
Drug: Clarithromycin, Amoxicillin, Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
Study: NCT04507321
Drug: GSK3640254 Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
Study: NCT04507321
Drug: [14C]-GSK3640254 intravenous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
Study: NCT04507321
Drug: [14C]-GSK3640254 powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
Study: NCT02010775
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
Study: NCT03560232
Drug: Cefazolin + Gentamicin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03560232
Drug: Clindamycin + Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT00674245
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once daily for 4 weeks
Study: NCT01044537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match PF-04937319 will be provided.
Study: NCT00774189
Drug: clarithromycin 250 mg tablets
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00425308
Drug: Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00425308
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00845637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
Study: NCT01647828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered IV
Study: NCT00680706
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine (100 mg) in 50 ml D5W, x 2.
Study: NCT01169753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet every morning for 2 weeks
Study: NCT00789308
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulation
Study: NCT00789308
Drug: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell proliferation inhibitor
Study: NCT00789308
Drug: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00789308
Drug: Simulect® (Basiliximab) - at 2nd or 3rd transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal IL-2 receptor blocker
Study: NCT00789308
Drug: Klexane® (Enoxaparinsodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation Prophylaxis
Study: NCT00680706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W (50 ml)
Study: NCT01403363
Drug: use of fentanyl patch that was halved
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
Study: NCT02462837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02233647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
Study: NCT03570645
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: block with only ropivacaine
Study: NCT03482180
Drug: KI1106 4g, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: KI1106 4 Capsules
Study: NCT03482180
Drug: Atorvastatin Calcium 20mg, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Calcium 20mg
Study: NCT01506622
Drug: Administration of fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.